Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iodixanol vs Iopamidol in Renal Impairment
NCT00209430Phase 4Completed
- Sponsor
- GE HealthCare
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of iodixanol in coronary artery disease (CAD) (2 arms), sponsored by GE HealthCare. Primary endpoints: Peak increase in Serum Creatinine and Incidence of contrast media-induced nephropathy at 3 days. Started Aug 2005; status: completed.
02
Drugs
iodixanol
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00209430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209430.